Loading...
XASE
VTAK
Market cap2mUSD
Jun 16, Last price  
0.35USD
1D
-5.48%
1Q
-13.53%
IPO
-100.00%
Name

Ra Medical Systems Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
5.31
EPS
Div Yield, %
Shrs. gr., 5y
215.04%
Rev. gr., 5y
-43.35%
Revenues
420k
-4.98%
5,976,0005,870,0006,257,0007,199,0004,405,00022,00014,000442,000420,000
Net income
-17m
L-76.42%
-4,202,000-17,765,000-30,832,000-56,957,000-36,045,000-25,070,000-26,865,000-70,572,000-16,643,000
CFO
-9m
L-55.04%
-1,886,000-5,523,000-18,508,000-33,173,000-28,304,000-27,625,000-22,568,000-20,619,000-9,271,000
Earnings
Aug 12, 2025

Profile

Ra Medical Systems, Inc., a medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular immune-mediated inflammatory diseases. It offers destruction of arteriosclerotic blockages by laser radiation ablation, a minimally invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. The company sells its products primarily through distributors in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.
IPO date
Sep 27, 2018
Employees
14
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
420
-4.98%
442
3,057.14%
14
-36.36%
Cost of revenue
314
505
10,038
Unusual Expense (Income)
NOPBT
106
(63)
(10,024)
NOPBT Margin
25.24%
Operating Taxes
3,141
3
Tax Rate
2,963.21%
NOPAT
(3,035)
(63)
(10,027)
Net income
(16,643)
-76.42%
(70,572)
162.69%
(26,865)
7.16%
Dividends
(5,158)
Dividend yield
Proceeds from repurchase of equity
5,968
8,238
18,906
BB yield
Debt
Debt current
275
275
37
Long-term debt
1,624
285
212
Deferred revenue
Other long-term liabilities
9,274
6,974
159
Net debt
(974)
(3,005)
(15,611)
Cash flow
Cash from operating activities
(9,271)
(20,619)
(22,568)
CAPEX
(67)
(76)
(17)
Cash from investing activities
(67)
(61)
21
Cash from financing activities
8,646
8,386
23,361
FCF
(2,982)
(167)
(6,253)
Balance
Cash
2,873
3,565
15,859
Long term investments
Excess cash
2,852
3,543
15,858
Stockholders' equity
(292,352)
(275,709)
(205,127)
Invested Capital
315,171
304,248
214,424
ROIC
ROCE
0.41%
EV
Common stock shares outstanding
3,264
5,495
1,034
Price
Market cap
EV
EBITDA
2,215
2,012
(9,603)
EV/EBITDA
Interest
91
3,078
Interest/NOPBT
85.85%